SJL/JOzarc

Strain description

MHC haplotype: H2^s
High incidence of reticulum cell sarcomas resembling Hodgkin’s disease by approximately one year of age.
Extreme aggression in males.
Susceptibility to experimental autoimmune encephalomyelitis (EAE) for multiple sclerosis research.
Spontaneous myopathy resulting from a splice-site mutation in the Dysferlin gene.
Good model for limb girdle muscular dystrophy 2B.
Increased rate of muscle regeneration after injury compared to BALB/c mice.
Resistance to infection by certain strains of mouse hepatitis virus MHV-4 due to mutation in Ceacam1.
Presence of the Trem2S148E allele – a naturally occurring variant.
Resistance to diet-induced atherosclerosis.
Carries the homozygous mutation for retinal degeneration, Pde6brd1.
Used as the male parent to produce the B6SJLF1 hybrid.
SJL mice are immunocompetent but have elevated levels of circulating T cells.

CBRI from Weizman Institute, Israel as F31. W.I. from Jackson Laboratory, (1975). Originally originated from Jackson Laboratory, USA 1938 43 from the cross of three separate sources of Swiss Webster stock. In 1955 inbreeding commenced from original stocks. Received from the Chester Beatty Research Institute, U.K. (1983) as F43. Caesarean derived to SPF status (1983).

The main research application for the SJL mice is in the study of cancer, especially Hodgkin’s disease. They are also used in research on atherosclerosis, diabetes, autoimmunity, demyelinating diseases, muscular dystrophy, virology, and retinal degeneration.